Millennium Management’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-324,422
| Closed | -$1.47M | – | 5960 |
|
|
2025
Q3 | $1.47M | Sell |
324,422
-17,918
| -5% | -$52.8K | ﹤0.01% | 4318 |
|
|
2025
Q2 | $736K | Buy |
+342,340
| New | +$958K | ﹤0.01% | 4637 |
|
|
2025
Q1 | – | Sell |
-42,847
| Closed | -$200K | – | 5793 |
|
|
2024
Q4 | $200K | Buy |
42,847
+13,608
| +47% | +$91.6K | ﹤0.01% | 5305 |
|
|
2024
Q3 | $205K | Sell |
29,239
-40,172
| -58% | -$292K | ﹤0.01% | 5436 |
|
|
2024
Q2 | $476K | Sell |
69,411
-179,231
| -72% | -$1.67M | ﹤0.01% | 4621 |
|
|
2024
Q1 | $3.52M | Buy |
248,642
+218,848
| +735% | +$3.33M | ﹤0.01% | 3230 |
|
|
2023
Q4 | $224K | Buy |
29,794
+15,879
| +114% | +$145K | ﹤0.01% | 5123 |
|
|
2023
Q3 | $209K | Buy |
13,915
+2,682
| +24% | +$48.2K | ﹤0.01% | 5098 |
|
|
2023
Q2 | $179K | Sell |
11,233
-10,866
| -49% | -$114K | ﹤0.01% | 5164 |
|
|
2023
Q1 | $159K | Sell |
22,099
-14,011
| -39% | -$99.1K | ﹤0.01% | 5264 |
|
|
2022
Q4 | $209K | Sell |
36,110
-50,232
| -58% | -$381K | ﹤0.01% | 5309 |
|
|
2022
Q3 | $820K | Sell |
86,342
-17,504
| -17% | -$230K | ﹤0.01% | 4507 |
|
|
2022
Q2 | $1.25M | Buy |
+103,846
| New | +$1.09M | ﹤0.01% | 4179 |
|
|
2022
Q1 | – | Sell |
-2,313
| Closed | -$41K | – | 6835 |
|
|
2021
Q4 | $41K | Sell |
2,313
-75,172
| -97% | -$1.5M | ﹤0.01% | 6514 |
|
|
2021
Q3 | $1.68M | Buy |
77,485
+76,336
| +6,644% | +$1.95M | ﹤0.01% | 4112 |
|
|
2021
Q2 | $40K | Buy |
+1,149
| New | +$61.9K | ﹤0.01% | 6390 |
|
|
2021
Q1 | – | Sell |
-2,599
| Closed | -$282K | – | 5845 |
|
|
2020
Q4 | $282K | Sell |
2,599
-15,279
| -85% | -$1.89M | ﹤0.01% | 4594 |
|
|
2020
Q3 | $1.84K | Sell |
17,878
-9,418
| -35% | -$1.41M | ﹤0.01% | 2663 |
|
|
2020
Q2 | $5.7M | Sell |
27,296
-10,505
| -28% | -$1.86M | 0.01% | 1640 |
|
|
2020
Q1 | $3.69M | Buy |
37,801
+35,764
| +1,756% | +$4.17M | 0.01% | 1563 |
|
|
2019
Q4 | $235K | Buy |
+2,037
| New | +$180K | ﹤0.01% | 3792 |
|
|
2019
Q1 | – | Sell |
-8,922
| Closed | -$281K | – | 3938 |
|
|
2018
Q4 | $281K | Sell |
8,922
-7,613
| -46% | -$310K | ﹤0.01% | 3246 |
|
|
2018
Q3 | $1M | Buy |
16,535
+1,013
| +7% | +$56.9K | ﹤0.01% | 2878 |
|
|
2018
Q2 | $823K | Sell |
15,522
-151,308
| -91% | -$9.1M | ﹤0.01% | 2939 |
|
|
2018
Q1 | $9.68M | Buy |
166,830
+142,688
| +591% | +$8.88M | 0.01% | 1350 |
|
|
2017
Q4 | $845K | Sell |
24,142
-761
| -3% | -$25K | ﹤0.01% | 2801 |
|
|
2017
Q3 | $909K | Sell |
24,903
-34,113
| -58% | -$947K | ﹤0.01% | 2569 |
|
|
2017
Q2 | $1.48M | Buy |
59,016
+29,903
| +103% | +$818K | ﹤0.01% | 2248 |
|
|
2017
Q1 | $786K | Sell |
29,113
-4,834
| -14% | -$137K | ﹤0.01% | 2539 |
|
|
2016
Q4 | $984K | Buy |
33,947
+32,753
| +2,743% | +$1.07M | ﹤0.01% | 2257 |
|
|
2016
Q3 | $49K | Sell |
1,194
-8,616
| -88% | -$327K | ﹤0.01% | 3187 |
|
|
2016
Q2 | $310K | Sell |
9,810
-13,085
| -57% | -$591K | ﹤0.01% | 2707 |
|
|
2016
Q1 | $1.18M | Sell |
22,895
-295
| -1% | -$16.5K | ﹤0.01% | 2092 |
|
|
2015
Q4 | $2.21M | Buy |
23,190
+15,190
| +190% | +$1.33M | ﹤0.01% | 1858 |
|
|
2015
Q3 | $659K | Sell |
8,000
-90,488
| -92% | -$11.6M | ﹤0.01% | 2509 |
|
|
2015
Q2 | $16M | Buy |
98,488
+88,052
| +844% | +$29.7M | 0.03% | 730 |
|
|
2015
Q1 | $4.23M | Sell |
10,436
-974
| -9% | -$412K | 0.01% | 1502 |
|
|
2014
Q4 | $6.16M | Buy |
+11,410
| New | +$4.4M | 0.01% | 1246 |
|
Millennium Management's ADVM Position: Q4 2025 in Review
Millennium Management sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 324,422 shares — an estimated $1.47M sold.
Millennium Management first reported a position in ADVM in Q4 2014 and held it in 38 quarters. The position peaked at $16M in Q2 2015. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Millennium Management reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Millennium Management sold 324,422 Adverum Biotechnologies shares in Q4 2025, an estimated $1.47M.
- Millennium Management first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 38 quarters.
- Millennium Management's Adverum Biotechnologies position peaked at $16M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.